| Ident. | Authors (with country if any) | Title |
|---|
| 001954 |
A. Kastner [France] ; E. C. Hirsch ; O. Lejeune ; F. Javoy-Agid ; O. Rascol [France] ; Yves Agid [France] | Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content ? |
| 001997 |
S. Holemans [Belgique] ; F. Javoy [France] ; Yves Agid [France] ; E. C. Laterre ; J.-M. Maloteaux | [3H]MK-801 binding to NMDA glutamatergic receptors in Parkinson's disease and progressive supranuclear palsy |
| 001A01 |
B. Pillon ; B. Dubois ; A. Ploska ; Yves Agid [France] | Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy |
| 001A09 |
E. C. Hirsch [France] ; J.-P. Brandel ; P. Galle ; F. Javoy-Agid ; Yves Agid [France] | Iron and aluminium increase in the substantia nigra of patients with Parkinson's disease : an X-ray microanalysis |
| 001A54 |
R. Raisman-Vozari ; J.-A. Girault ; S. Moussaoui ; C. Feuerstein ; P. Jenner ; C. D. Marsden ; Yves Agid [France] | Lack of change in triatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man |
| 001A56 |
E. C. Hirsch ; C. Duyckaerts ; F. Javoy-Agid ; J.-J. Hauw ; Yves Agid [France] | Does adrenal graft enhance recovery of dopaminergic neurons in Parkinson's disease ? |
| 001A57 |
F. Javoy-Agid ; E. C. Hirsch ; S. Dumas ; C. Duyckaerts ; J. Mallet ; Yves Agid [France] | Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease : an in situ hybridization study |
| 001A58 |
D. T. Dexter [Royaume-Uni] ; A. Carayon ; M. Vidailhet ; M. Ruberg ; F. Agid ; Yves Agid [France] ; A. J. Lees ; F. R. Wells ; P. Jenner ; C. D. Marsden | Decreased ferritin levels in brain in Parkinson's disease |
| 001A59 |
B. Dubois ; B. Pillon ; F. Lhermitte ; Yves Agid [France] | Cholinergic deficiency and frontal dysfunction in Parkinson's disease |
| 001A60 |
M. Ruberg ; W. Mayo ; A. Brice ; C. Duyckaerts ; J. J. Hauw ; H. Simon ; M. Lemoal ; Yves Agid [France] | Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions |
| 001A61 |
S. Malessa ; E. C. Hirsch ; P. Cervera ; C. Duyckaerts ; Yves Agid [France] | Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes : a quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy, and striatonigral degeneration |
| 001A63 |
B. Dubois ; B. Pillon ; N. Sternic ; F. Lhermitte ; Yves Agid [France] | Age-induced cognitive disturbances in Parkinson's disease |
| 001A93 |
D. Scherman ; C. Desnos ; F. Darchen ; P. Pollak ; F. Javoy-Agid ; Yves Agid [France] | Striatal dopamine deficiency in Parkinson's disease: role of aging |
| 001A99 |
B. Pillon ; B. Dubois ; G. Cusimano ; A.-M. Bonnet ; F. Lhermitte ; Yves Agid [France] | Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? |
| 001B00 |
B. Pillon ; B. Dubois ; A.-M. Bonnet ; M. Esteguy ; J. Guimaraes ; J.-M. Vigouret ; F. Lhermitte ; Yves Agid [France] | Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test |
| 001B22 |
J. Epelbaum ; F. Javoy-Agid ; A. Enjalbert ; S. Krantic ; C. Kordon ; Yves Agid [France] | Somatostatin concentrations and binding sites in human frontal cortex are differentially affected in Parkinson's disease associated dementia and in progressive supranuclear palsy |
| 001B23 |
B. Dubois ; B. Pillon ; F. Legault ; Yves Agid [France] ; F. Lhermitte | Slowing of cognitive processing in progressive supranuclear palsy: a comparison with Parkinson's disease |
| 001B24 |
S. Jegou ; F. Javoy-Agid ; C. Delbende ; D. Tranchand-Bunel ; D. H. Coy ; Yves Agid [France] ; H. Vaudry | Regional distribution of vasoactive intestinal peptide in brains from normal and parkinsonian subjects |
| 001B29 |
L. Pierot ; C. Desnos ; J. Blin ; R. Raisman ; D. Scherman ; F. Javoy-Agid ; M. Ruberg ; Yves Agid [France] | D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy |
| 001B52 |
P. Dealy-Goyet ; J.-M. Zajac ; F. Javoy-Agid ; Yves Agid [France] ; B. P. Roques | Regional distribution of μ, σ and k opioid receptors in human brains from controls and parkinsonian subjects |
| 001B62 |
R. Cash ; R. Raisman ; A. Ploska ; Yves Agid [France] | Dopamine D-1 receptor and cyclic AMP-dependent phosphorylation in Parkinson's disease |
| 001B64 |
A.-M. Bonnet ; Y. Loria ; M.-H. Saint-Hilaire ; F. Lhermitte ; Yves Agid [France] | Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? |
| 001B65 |
B. Dubois ; F. Danze ; B. Pillon ; G. Cusimano ; F. Lhermitte ; Yves Agid [France] | Cholinergic-dependent cognitive deficits in Parkinson's disease |
| 001B66 |
A. M. Bonnet ; G. Tell ; P. J. Schechter ; J. Grove ; M. H. Saint-Hilaire ; Y. De Smet ; Yves Agid [France] | Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea |
| 001B67 |
J. Epelbaum ; F. Javoy-Agid ; E. Hirsch ; J. J. Hauw ; C. Kordon ; S. Krantic ; Yves Agid [France] | Brain somatostatin concentrations do not decrease in progressive supranuclear palsy |
| 001B68 |
M. Ruberg ; A. Villageois ; A.-M. Bonnet ; B. Pillon ; F. Rieger ; Yves Agid [France] | Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems |
| 001B77 |
Yves Agid [France] ; H. Taquet ; F. Cesselin ; J. Epelbaum ; F. Javoy-Agid | Neuropeptides and parkinson's disease |
| 001B79 |
B. Pillon ; B. Dubois ; F. Lhermitte ; Yves Agid [France] | Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson's disease, and Alzheimer's disease |
| 001B81 |
B. Dubois ; B. Pillon ; H. De Saxce ; F. Lhermitte ; Yves Agid [France] | Disappearance of Parkinsonian signs after spontaneous vascular ``thalamotomy'' |
| 001B96 |
J. C. Monfort ; F. Javoy-Agid ; J. J. Hauw ; B. Dubois ; Yves Agid [France] | Brain glutamate decarboxylase in Parkinson's disease with particular reference to a premortem severity index |
| 001C01 |
B. Bokobza ; M. Ruberg ; B. Scatton ; F. Javoy-Agid ; Yves Agid [France] | [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy |
| 001C03 |
D. Rougemont ; J. C. Baron ; P. Collard ; P. Bustany ; D. Comar ; Yves Agid [France] | Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease |
| 001C04 |
C. Llorens-Cortes ; F. Javoy-Agid ; Yves Agid [France] ; H. Taquet ; J. C. Schwartz | Enkephalinergic markers in substantia nigra and caudate nucleus from Parkinsonian subjects |
| 001C06 |
R. Cash ; M. Ruberg ; R. Raisman ; Yves Agid [France] | Adrenergic receptors in Parkinson's disease |
